AptaBio Therapeutics Inc. (KOSDAQ: 293780)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,660.00
+440.00 (5.35%)
Sep 12, 2024, 10:54 AM KST
-22.12%
Market Cap 183.30B
Revenue (ttm) 2.06B
Net Income (ttm) -15.76B
Shares Out 22.30M
EPS (ttm) -706.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,675
Open 8,290.00
Previous Close 8,220.00
Day's Range 8,290.00 - 8,700.00
52-Week Range 4,930.00 - 15,490.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About AptaBio Therapeutics

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 293780
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.